Neurogene Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Neurogene Inc. (NGNE) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021
Period EndingDec 2024Dec 2023Dec 2022Dec 2021
Operating Activities
Net Income-75.14-36.32-55.19-50.52
Depreciation & Amortization3.253.303.200.95
Stock Based Compensation8.321.421.250.90
Change in Working Capital-5.96-4.02-2.701.60
Change in Accounts Payable-0.080.67-3.612.98
Change in Other Working Capital1.26-15.690.91-1.39
Other Operating Activities1.26-15.690.610.68
Net Cash from Operating Activities-70.60-51.42-52.82-46.40
Investing Activities
Capital Expenditures-0.81-0.32-2.23-18.37
Acquisitions0.0020.960.000.00
Purchases of Investments-198.455.000.000.00
Sales/Maturities of Investments74.005.000.000.00
Net Cash from Investing Activities-125.2625.64-2.23-18.37
Financing Activities
Debt Repayment-0.05-0.030.000.00
Common Stock Issued189.5992.340.070.29
Other Financing Activities-7.1492.340.000.00
Net Cash from Financing Activities184.0792.4866.5351.06
Summary
Net Change in Cash-11.7966.7011.48-13.71
Cash at Beginning of Period148.7282.0270.5484.25
Cash at End of Period136.93148.7282.0270.54
Free Cash Flow-71.41-51.74-55.05-64.77
Supplemental Disclosures
Interest Paid0.010.010.000.00